The Limbic

Lung cancer screening in 2020: What does the evidence say?

In this podcast series we speak to Professor Kwun Fong, Thoracic and Sleep Physician at The Prince Charles Hospital in Brisbane, and Professor David Baldwin from Nottingham City Hospital in the UK about the pros and cons of national lung...

In this podcast series we speak to Professor Kwun Fong, Thoracic and Sleep Physician at The Prince Charles Hospital in...

Lung cancer outcomes gap still wide for Indigenous Australians

Indigenous people with lung cancer are much more likely to die than non-Indigenous people, despite having similar stage at diagnosis and receiving similar treatments, a new study from the NT has found. A review of outcomes for 91 Indigenous and...

Indigenous people with lung cancer are much more likely to die than non-Indigenous people, despite having similar stage at diagnosis...

Podcast: Prof. Nick Pavlakis on key advances in lung cancer management over the past decade

Lung cancer screening in 2020: What does the evidence say?

Lung cancer outcomes gap still wide for Indigenous Australians

Call for lung cancer specialist nurse funding

Osimertinib could be new standard of care for EGFRm NSCLC

A/Prof Nick Pavlakis: how lung cancer care has changed in the COVID-19 pandemic

Lung cancer linked to higher mortality in COVID-19

Lung cancer conference: Associate Professor Nick Pavlakis on the steps to improving care

ALCC 2020: Lung cancer screening works – it’s time to do it

Case for targeted lung cancer screening bolstered by NELSON results, experts say

PBS broadens access to COPD triple therapy and lung cancer immunotherapy

Vaping backed for smoking cessation in ‘pragmatic’ new RACGP guidelines

Lung Foundation seeks help to counter Big Tobacco’s latest toxic product

Disappointing results for mesothelioma trial

Atezolizumab shows OS benefit over chemo in PD-L1 high NSCLC

First KRAS-targeted therapy for lung cancer shows promise

Vaping-NRT combination boosts smoking quit rates

Minister requests feasibility study for lung cancer screening

Lung cancer: personalised medicine to be delivered by ‘molecular champions’

PBS allows unrestricted pemetrexed use in first-line treatment of NSCLC

‘Non-expandable lung’ common finding in mesothelioma patients

Atezolizumab-based combination gets first line approval for metastatic NSCLC

1 in 4 patients with advanced NSCLC alive at 5 years with immunotherapy

Infographic shows modern day benefits and harms of lung cancer screening

National Dust Diseases Taskforce to be set up this year

Respiratory physician wins case against asbestos industry lobbyist

Professor Ian Yang: exploring coexisting COPD and lung cancer

Advanced lung cancer patients get real benefits from home exercise support

Functional decline at end of life shows ‘tipping point’ in respiratory patients

Woolcock’s lung cancer centre leader looks to microbiome

Room to improve care for stage lll NSCLC

RACP calls for urgent action on dust diseases recommendations

SABR the treatment of choice for inoperable stage 1 NSCLC

$4 million launch for National Strategic Action Plan for Lung Conditions

Lung cancer still diagnosed in emergency settings

CHEST Australia trial shows it’s an uphill challenge to detect lung cancer early

Crizotinib and osimertinib listed on PBS for lung cancer

Lung Foundation launches campaign to tackle lack of empathy for lung cancer

Lung cancer deaths still increasing

Lung cancer screening within 5 years – but will it target the right people?

Pembrolizumab gets PBS listing for first line treatment of advanced NSCLC

Key reforms needed to avoid disjointed care for lung cancer patients: LFA

Respiratory physician elected to Academy in recognition of medical research

Don’t look for lung cancers on coronary CT angiograms

Malignant pleural effusions: the jury is still out on definitive management

Deprescribing call for lung cancer patients taking unnecessary medicines

Big Tobacco vs Australia’s Plain Packaging

Young women with lung cancer face early menopause from chemo

Push to deregulate e-cigs in UK

Lung cancer patients benefit from brachytherapy palliation

Lung cancer diagnosis difficulties highlighted in NSW study

Have your say on National Strategic Action Plan for Lung Conditions

Lung cancer patients pay more than $20,000 in upfront fees

Palliative care group opposes opioid prescribing curbs

Row over lung cancer drug deal

Novel therapies begin to ‘outsmart’ ALK-positive NSCLC

Lung cancer’s other side effect: financial toxicity

Immune therapy benefits confirmed in NSCLC

Liquid biopsy could replace lung tissue biopsy: Australian trial

Checkpoint inhibitors show potential for first line use in NSCLC

Lung cancer screening hurdles become apparent in ILST

Ask the right questions for lung cancer symptom control: Prof David Currow

ATLANTIC trial shows immune checkpoint inhibitors may have role in advanced NSCLC

Nicotine cap on e-cigs ‘too low’, inquiry told

Asbestos-related lung disease risk will persist, researchers warn

UK: First guidelines for the management of mesothelioma

Professor Kwun Fong: What does 2018 hold for lung cancer?

Modest investment will cut hospitalisations and deaths from lung disease: Lung Foundation

Pilot lung health checks identifying cancer in high-risk

Evidence builds to support lung cancer screening in high-risk

Questions raised about follow-up after lung cancer treatment

Survey finds lack of empathy for people with lung cancer

No urgency to bring in early palliative care for mesothelioma

Precautionary principle is ‘immoral’, vaping inquiry hears

Hundreds of lung cancer cases caused by silica dust

Heart trial finds lung cancer benefit

How checkpoint inhibitors are changing the outlook for lung cancer patients

Lung Foundation welcomes new option for advanced lung cancer

Big tobacco’s role in vaping inquiry leaves TSANZ fuming

Closing in on targeted therapy for lung SCC

GPs unlikely to pick up certain cancers right away because its not the most likely diagnosis